{
    "clinical_study": {
        "@rank": "48424", 
        "acronym": "Qualipec", 
        "arm_group": {
            "arm_group_label": "PecFent\u00ae"
        }, 
        "brief_summary": {
            "textblock": "National multicenter, prospective, observational study in cancer patients with chronic\n      background pain and breakthrough pain to whom PecFent\u00ae has been prescribed under pragmatic\n      condition by a specialist in the treatment of cancer pain conditions.\n\n      \u2022 Study objectives include assessment of early treatment satisfaction."
        }, 
        "brief_title": "Patient Satisfaction and Quality of Life Impact - PecFent\u00ae", 
        "condition": "Breakthrough Cancer Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult (aged \u226518 years) with cancer\n\n          -  Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic\n             background pain"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Cancer patients with breakthrough pain"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693328", 
            "org_study_id": "CP057/11"
        }, 
        "intervention": {
            "arm_group_label": "PecFent\u00ae", 
            "intervention_name": "PecFent\u00ae (fentanyl) nasal spray", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fentanyl"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "quality of life", 
            "PecFent", 
            "Lazanda", 
            "fentanyl", 
            "intranasal", 
            "breakthrough cancer pain"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "jerome.fayette@lyon.unicancer.fr", 
                "last_name": "Jerome Fayette, MD", 
                "phone": "+33487785451"
            }, 
            "facility": {
                "address": {
                    "city": "Lyon", 
                    "country": "France"
                }, 
                "name": "Centre L\u00e9on-B\u00e9rard"
            }, 
            "investigator": {
                "last_name": "Jerome Fayette, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent\u00ae for the Treatment of Breakthrough Cancer Pain (BTPc)", 
        "overall_contact": {
            "email": "sylvieallouchecovarrubias@archimedespharma.com", 
            "last_name": "Sylvie Allouche, MD", 
            "phone": "+33155702320"
        }, 
        "overall_official": {
            "affiliation": "Head of Pain Federation - Palliative Medicine Lariboisiere Hospital, Paris France", 
            "last_name": "Alain Serrie, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Satisfaction will be assessed using a 4-point Likert scale.", 
            "measure": "Satisfaction", 
            "safety_issue": "No", 
            "time_frame": "Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent\u00ae from completion of titration through Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Archimedes Development Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Archimedes Development Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}